The global precocious puberty treatment market is anticipated to attain an impressive valuation of USD 1,716.43 million in 2023 and is projected to reach USD 3,650.66 million by 2033, trailing a CAGR of 7.8% during the forecast period.
Rising focus of key players on research to develop novel drugs and expand the indication label of currently available drugs for treatment of precocious puberty is anticipated to fuel the precocious puberty treatment market growth during the forecast period.
On the other hand, the number of children suffering from hormonal disorders is increasing due to various types of inherited factors and abnormal functioning of endocrine glands. These hormonal disorders mainly growth hormone disorder led the children to adopt early puberty symptoms which affects the height and other growth phenomenon in children.
Thus, augmenting market growth. Moreover, with the rising prevalence of overactive growth hormone, children are more likely to suffer from precocious puberty. This suggests that rising prevalence of hormonal disorders are anticipated to fuel the precocious puberty treatment market growth during the forecast period.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | USD 1,716.43 million |
| Anticipated Forecast Value (2033) | USD 3,650.66 million |
| Projected Growth Rate (2023 to 2033) | CAGR 7.8% |
Explore FMI!
Book a free demo
The market for precocious puberty treatment was worth USD 1,310 million in 2018, while growing at a CAGR of 5.5 % during the historical period. The market's growth is driven by an increase in the number of research and development activities. This will offer lucrative opportunities for growth in the precocious puberty treatment market during the projected period. Moreover, increasing drug approvals and launches will further drive growth of this market.
Similarly, increasing investments for the development of advanced technologies and surging number of emerging markets will further provide beneficial opportunities for precocious puberty treatment market growth during the forecast period. On the other hand, higher effectiveness of triptorelin in the suppression of gonadotropin in Central Precocious Puberty (CPP) among young boys and girls is anticipated to propel precocious puberty treatment market growth.
For example, according to data published in the Scientific World Journal, in May 2012, triptorelin 11.25 mg per 90 days efficiently suppressed the pituitary-gonadal level in children with central precocious puberty from first administration. This will create more space and opportunities for market expansion. After a comprehensive analysis of above-mentioned factors, the industry for precious puberty treatment is projected to be worth USD 3650.66 million by end of the forecast period.
Use of approved therapies will propel treatment market of precocious puberty
The use of Triptodor (triptorelin), Lupron Depot-Ped (leuprolide acetate), and Supprelin LA (histrelin acetate) in treatment of precocious puberty are anticipated to fuel growth in this market. These gonadotropin-releasing hormone (GnRH) agonists are approved therapies used in treating central precocious puberty.
These agonists are used to prolong the suppression of gonadotropin secretion when required which is expected to augment the market growth. Moreover, use of triptorelin, a GnRH agonist, effectively suppresses the pituitary-gonadal axis and pubertal development in children affected with precocious puberty that is also estimated to propel growth in the market of precocious puberty treatment during the projected period. The increasing prevalence of hormonal disorders is expected to positively influence the market growth. Also, the rising incidences of obesity will propel growth during the forecast period.
Another crucial factor driving growth rate of precocious puberty treatment market is the increasing healthcare expenditure which helps in enhancing its infrastructure. Moreover, increasing initiatives by public and private organizations to spread awareness are also expected to expand precocious puberty treatment market. High disposable income and rising demand for disease-specific treatments will also result in the expansion of precocious puberty treatment market. Similarly, increasing use of radiation or chemotherapy for treatment of cancer and sedentary lifestyle of people will drive the market in the forecast period.
High cost of treatment and lack of skilled professionals to hold back market growth
The high cost associated with the treatment is projected to restrain market growth. The lack of skilled professionals and dearth of healthcare infrastructure in developing economies will challenge the precocious puberty treatment market during the forecast period.
Furthermore, a drop in clinical visits due to COVID-19 outbreak and dearth of awareness among people will also act as restrain and will further obstruct growth market during the forecast period.
North America to dominate the market with maximum share
The demand for treatment options of precocious puberty in North America is projected to be maximum in the forecast period. This region is expected to dominate the market by reaching USD 1,704.8 million by end of the forecast period. This region is estimated to possess 46.7% market share by end of 2033 with CAGR of 7.1% during the forecast period.
North America is expected to hold a dominant position in the global central precocious puberty market over the forecast period, due to the growing availability of drugs for the treatment of precocious puberty in this region. For example, in October 2017, Arbor Pharmaceuticals, LLC and Debiopharm International SA declared the commercial availability of Triptodur in the region for the treatment of pediatric patients aged two years and older who are diagnosed with central precocious puberty (CPP). This development will benefit the market in the long run.
The growth is also attributed to rising clinical trials and proliferation in research development activities for prevention of hormonal misbalance among the children. In this region, the United States is dominating the market because of the increasing prevalence of obesity leading to early puberty among the children.
East Asian market driving growth with fastest CAGR
The market of precocious puberty treatment in East Asia is estimated to witness fastest CAGR of 7.6% during the forecast period. This region is anticipated to possess 25% market share by end of 2033. Furthermore, market in this region will be worth USD 912.6 million by end of the projected period.
The growth is attributable to factors such as presence of vast number of companies and increasing acceptance of treatment related to early puberty. In this region, Japan is dominating the growth of East-Asia precocious puberty treatment market due to rising prevalence of precocious puberty and rising girl population in this region.
Triptorelin will fuel growth with maximum market share
This segment is anticipated to withhold 62% market share by end of the forecast period. This segment will also witness fastest CAGR growth of 9% during the forecast period. The growth is attributed to factors such as use of triptorelin as a first line therapy in treatment of precocious puberty. A new triptorelin 11.25 mg long depot formulation is now available for the treatment of precocious puberty which is regarded as the best treatment for girl child till date. The 3-month depot triptorelin is a satisfactory alternative for the therapy of children affected with precocious puberty. The rising adoption of this alternative in treating this disease is propelling the growth of this segment. Moreover, the longer intervals between injections during the period of therapy may increase acceptability and compliance with treatment. These factors are expected to fuel growth of this segment by 2033.
Hospitals pushing growth with significant market share
The hospital segment dominated the market of precocious puberty treatment in 2022, with a market share of 48.75%. This segment is anticipated to sustain its dominance by accounting for more than 58% market share by end of the forecast period. This segment will grow with a moderate CAGR of 6.1% during the projected period.
The growth is attributed to factors such as high availability of skilled professionals in hospitals and robust and organized healthcare infrastructure. Moreover, easy access of gonadotropin-releasing hormone agonist for treating precocious puberty disorder in these facilities will propel growth of this segment during the forecast period.
Start-ups help in understanding the growth outlook of any industry. These new companies have the potential to generate high returns which directly benefits the growth of any market. These start-ups are naturally more efficient at converting inputs into outputs with more flexibility and adaptability in nature, able to shift quickly in response to volatile market conditions. Some of the start-ups that will fuel the expansion of precocious puberty treatment market are:
The precocious puberty treatment market is extremely competitive and consists of various key market players. These players are developing novel delivery systems for treating precocious puberty. This is anticipated to fuel precocious puberty treatment market. The key players in this market are: Teva Pharmaceutical Industries Ltd, AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc, Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, Sun Pharmaceutical Industries Limited, and Sanofi S.A.
Key industry players are inclined on adoption of inorganic growth strategies like acquisition, partnerships, and collaboration in order to bolster their product portfolio. This is expected to propel the global precocious puberty treatment market.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 1,716.43 million |
| Market Value in 2033 | USD 3,650.66 million |
| Growth Rate | CAGR of 7.8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Drug Class, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Teva Pharmaceutical Industries Ltd; AbbVie Inc.; Arbor Pharmaceuticals, LLC; Pfizer Inc.; Tolmar Pharmaceuticals, Inc.; Endo International Plc.; Ipsen Pharma; Debiopharm Group; Sun Pharmaceutical Industries Limited; Sanofi S.A |
| Customization | Available Upon Request |
The market is valued at USD 1,716.43 million in 2023.
From 2018 to 2022, the market registered a 5.5 % CAGR.
By 2033, the market is likely to reach USD 3,650.66 million.
The market is estimated to record a CAGR of 7.8% from 2023 to 2033.
North America’s market is expected to register a 7.1% CAGR until 2033.
Home Respiratory Therapy Market – Growth & Forecast 2025 to 2035
Veterinary Auto-Immune Therapeutics Market Growth - Trends & Forecast 2025 to 2035
Radial Compression Devices Market Growth - Trends & Forecast 2025 to 2035
Digital Telepathology Market is segmented by Application and End User from 2025 to 2035
Suture Anchor Devices Market Is Segmented by Product Type, Material Type, Tying and End User from 2025 to 2035
Home Infusion Therapy Devices Market - Growth & Forecast 2025 to 2035
Precocious Puberty Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
